Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03055897Not ApplicableCompleted

Tear Film Innovations iLux Safety Study

Role: lead

NCT03055832Not ApplicableCompleted

Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction

Role: lead

NCT03055650Not ApplicableCompleted

iLux Treatment for Meibomian Gland Dysfunction (MGD)

Role: lead

All 3 trials loaded